Evidence map›Paper›PMID 38773172›Full record

ArticleScientific reports2024

Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug.

Nima Akhavein, Marc M Baum, Manjula Gunawardana, John A Moss, Sandrine Calvez, Mariana Remedios-Chan, Rob Fanter, Steve Lenhard, Samantha Rusk, Leonard Azzarano and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nima AkhaveinViiV Healthcare, Five Moore Drive, Research Triangle Park, NC, 27709, USA. nima.2.akhavein@viivhealthcare.com.
Marc M BaumDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
Manjula GunawardanaDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
John A MossDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
Sandrine CalvezDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
Mariana Remedios-ChanDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
Rob FanterDepartment of Chemistry, Oak Crest Institute of Science, 128‑132 W. Chestnut Ave., Monrovia, CA, 91016, USA.
Steve LenhardGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Samantha RuskGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Leonard AzzaranoGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Deborah McCoyGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Beat JuckerGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Brian JohnsViiV Healthcare, Five Moore Drive, Research Triangle Park, NC, 27709, USA.
Matt BurkeGlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
Emile VelthuisenViiV Healthcare, Five Moore Drive, Research Triangle Park, NC, 27709, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GSK2838232 (GSK8232) is a second-generation maturation inhibitor (MI) developed for the treatment of HIV with excellent broad-spectrum virological profiles. The compound has demonstrated promising clinical results as an orally administered agent. Additionally, the compound's physical and pharmacological properties present opportunities for exploitation as long-acting parenteral formulations. Despite unique design constraints including solubility and dose of GSK8232, we report on three effective tunable drug delivery strategies: active pharmaceutical ingredient (API) suspensions, ionic liquids, and subdermal implants. Promising sustained drug release profiles were achieved in rats with each approach. Additionally, we were able to tune drug release rates through a combination of passive and active strategies, broadening applicability of these formulation approaches beyond GSK8232. Taken together, this report is an important first step to advance long-acting formulation development for critical HIV medicines that do not fit the traditional profile of suitable long-acting candidates.

Indexed as

Drug LiberationAnimalsAnti-HIV AgentsAnti-Retroviral AgentsDelayed-Action PreparationsDrug Delivery SystemsHIV InfectionsHydrophobic and Hydrophilic InteractionsIonic LiquidsMaleRatsRats, Sprague-DawleySolubilityAnti-HIV AgentsAnti-Retroviral AgentsDelayed-Action PreparationsIonic LiquidsHIV PrEPIonic liquidsLong-acting HIV treatmentMaturation inhibitorSubdermal implantsSustained release drug delivery

Identifiers

PMID38773172
PMCPMC11109207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.